COVID-19 and liver injury: where do we stand?

This item is provided by the institution :
Hellenic Society of Gastroenterology   

Repository :
Annals of Gastroenterology   

see the original item page
in the repository's web site and access all digital files if the item*



COVID-19 and liver injury: where do we stand? (EN)

Deutsch, Melanie
Vasileiadi, Sofia
Papadopoulos, Nikolaos

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

2020-08-12


The coronavirus SARS-CoV-2 was identified as the cause of COVID-19, a severe acute respiratory syndrome. Several clinical studies refer to liver injury as the most frequent clinical extrapulmonary manifestation. In this review, we summarize the available clinical data concerning liver injury during COVID-19. Although the underlying mechanism of liver impairment is somewhat unclear, transaminases and bilirubin levels are elevated in a substantial proportion of patients. Moreover, more severe alterations in liver enzymes may correlate with a worse clinical course of COVID-19. However, several other cofactors, such as drug-induced liver injury, hyper-inflammatory response to infection, hypoxic hepatitis or preexisting underlying liver disease, cannot be excluded. Keywords Coronavirus, SARS-CoV-2, COVID-19, liver injury Ann Gastroenterol 2020; 33 (5): 459-464 (EN)


English

Hellenic Society of Gastroenterology (EN)


1792-7463
1108-7471
Annals of Gastroenterology; Volume 33, No 5 (2020); 459 (EN)

Copyright (c) 2020 Annals of Gastroenterology (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)